November 25, 2002

FOR: ZOLL Medical Corporation

Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832


ZOLL and Cardiac Science Settle Patent Infringement Lawsuit

Monday, November 25, 2002 – 
BURLINGTON, Mass and IRVINE, Calif, November 25, 2002 - ZOLL Medical Corporation (Nasdaq: ZOLL) and Cardiac Science Inc (Nasdaq: DFIB), both developers and manufacturers of automated public access defibrillators (AEDs) and other medical devices, jointly reported today that they have settled a patent infringement action brought by Cardiac Science against ZOLL in March 2002.

The settlement agreement includes the cross licensing of a number of patents between the two parties including those in question in the lawsuit. Under the agreement, Cardiac Science will receive an undisclosed initial licensing fee and certain ongoing royalties. Further terms of the settlement were not disclosed. Additionally, both parties will avoid previously anticipated significant legal costs.

ZOLL President and Chief Executive Officer, Richard A. Packer and Cardiac Science President and CEO, Raymond W. Cohen said in a joint statement that the settlement is positive for both organizations since it eliminates uncertainty and avoids the distraction stemming from the patent litigation. The settlement also clears the way for a robust competitive AED landscape.

The Cardiac Science suit alleged that the ZOLL automated external defibrillator sold under the name “AED Plus,” infringed Cardiac Science United States Patent numbers 5,579,919 and 6,125,299, entitled “Medical Electrode Packaging Technology,” and “AED With Force Sensor,” respectively.

About ZOLL Medical Corporation

ZOLL Medical Corporation, headquartered in Burlington, MA, designs, manufactures and markets an integrated line of proprietary, non-invasive resuscitation devices and disposable electrodes. Used by health care professionals to provide both types of cardiac resuscitation—pacing and defibrillation—these products are essential in the emergency treatment of cardiac arrest victims, both inside and outside the hospital. ZOLL also designs and markets software that automates collection and management of both clinical and non-clinical data for emergency medical service providers. ZOLL has operations in the United States, Canada, United Kingdom, Germany, France, the Netherlands and Australia, and business partners in all of the world’s major markets. For more information about ZOLL and its products, visit

About Cardiac Science

Cardiac Science develops, manufactures and markets Powerheart®-brand automated portable public access defibrillators, Diascope® brand patient monitors as well as Powerheart Cardiac Rhythm Module, the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science holds 69 issued patents relating to external defibrillation devices and proprietary technology. Cardiac Science products are marketed in the United States by its 55-person direct sales force and by international distributors in more than 50 countries around the world. For more information, please visit Cardiac Science at

Certain statements contained in this press release, including statements regarding the anticipated development of ZOLL’s business, the intent, belief or current expectations of ZOLL, its directors or its officers, primarily with respect to ZOLL’s business model and future operating performance of ZOLL, including expectations regarding results in future periods, operating performance and contributions to results from ZOLL’s new Public Access Defibrillation product, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the ZOLL’s Annual Report on Form 10-Q filed on August 14, 2002, the future performance of the direct sales operations, the outcome of a pending patent infringement suit relating to the ZOLL AED Plus, as well as uncertainties regarding the market, acceptance and profitability of the ZOLL AED Plus and M Series CCT, the length and severity of the current economic slowdown and its impact on capital spending budgets, the reduction in overall capital equipment expenditures in the hospital and pre-hospital markets, the potential disruption in the transportation industry on ZOLL’s supply chain and product distribution channels, and the desire or ability of other parties to purchase ZOLL’s products.